Skip to main content
. 2021 Nov 25;23(5):485–493. doi: 10.1111/hiv.13206

TABLE 2.

Types of malignancy

Malignancy type N = 4305
N % a % b
AIDS‐defining cancers 2432 (49.5%) (8.7%)
Non‐Hodgkin lymphoma 1808 (36.8%) (6.4%)
Kaposi sarcoma 701 (14.3%) (2.5%)
Burkitt lymphoma 116 (2.4%) (0.4%)
Cervix uteri 66 (1.3%) (0.2%)
Non‐AIDS‐defining cancers 2485 (50.5%) (8.8%)
Bronchus and lung 303 (6.2%) (1.1%)
Liver and intrahepatic bile ducts 277 (5.6%) (1.0%)
Stomach 228 (4.6%) (0.8%)
Malignant neoplasm, without specification of site 183 (3.7%) (0.7%)
Secondary malignant neoplasm of bone and bone marrow 140 (2.8%) (0.5%)
Secondary malignant neoplasm of brain and cerebral meninges 100 (2.0%) (0.4%)
Multiple myeloma 98 (2.0%) (0.3%)
Rectosigmoid junction and rectum 94 (1.9%) (0.3%)
Secondary malignant neoplasm of lung 86 (1.7%) (0.3%)
Sigmoid colon 52 (1.1%) (0.2%)
Oesophagus 47 (1.0%) (0.2%)
Breast 44 (0.9%) (0.2%)
Acute myeloblastic leukaemia (AML) 39 (0.8%) (0.1%)
Skin of trunk 28 (0.6%) (0.1%)

N = 4305 people living with HIV (PLWH) with malignancy; PLWH may have more than one type of malignancy.

a

% among 4917 malignancies.

b

% among 28 089 total PLWH cohort.